[go: up one dir, main page]

HK1204958A1 - Methods and compositions for preventing or treating ophthalmic conditions - Google Patents

Methods and compositions for preventing or treating ophthalmic conditions Download PDF

Info

Publication number
HK1204958A1
HK1204958A1 HK15105695.0A HK15105695A HK1204958A1 HK 1204958 A1 HK1204958 A1 HK 1204958A1 HK 15105695 A HK15105695 A HK 15105695A HK 1204958 A1 HK1204958 A1 HK 1204958A1
Authority
HK
Hong Kong
Prior art keywords
arg
phe
peptide
lys
dmt
Prior art date
Application number
HK15105695.0A
Other languages
English (en)
Chinese (zh)
Inventor
Liping Liu
Shibo Tang
Xiaoling Liang
Original Assignee
Stealth Peptides International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International, Inc. filed Critical Stealth Peptides International, Inc.
Publication of HK1204958A1 publication Critical patent/HK1204958A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15105695.0A 2009-08-24 2015-06-16 Methods and compositions for preventing or treating ophthalmic conditions HK1204958A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US23644009P 2009-08-24 2009-08-24
US236440P 2009-08-24
US23774509P 2009-08-28 2009-08-28
US237745P 2009-08-28
US34847010P 2010-05-26 2010-05-26
US348470P 2010-05-26

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
HK16107814.1A Division HK1219674A1 (en) 2009-08-24 2015-06-16 Methods and compositions for preventing or treating opthalmic conditions
HK16105839.6A Division HK1217900A1 (en) 2009-08-24 2015-07-20 Methods and compositions for preventing or treating opthalmic conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK16107814.1A Addition HK1219674A1 (en) 2009-08-24 2015-06-16 Methods and compositions for preventing or treating opthalmic conditions

Publications (1)

Publication Number Publication Date
HK1204958A1 true HK1204958A1 (en) 2015-12-11

Family

ID=43628336

Family Applications (4)

Application Number Title Priority Date Filing Date
HK15105695.0A HK1204958A1 (en) 2009-08-24 2015-06-16 Methods and compositions for preventing or treating ophthalmic conditions
HK15106883.0A HK1206258A1 (en) 2009-08-24 2015-07-20 Methods and compositions for preventing or treating ophthalmic conditions
HK16105839.6A HK1217900A1 (en) 2009-08-24 2015-07-20 Methods and compositions for preventing or treating opthalmic conditions
HK18107246.7A HK1247821A1 (zh) 2009-08-24 2018-06-01 用於预防或治疗眼科病症的方法和组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK15106883.0A HK1206258A1 (en) 2009-08-24 2015-07-20 Methods and compositions for preventing or treating ophthalmic conditions
HK16105839.6A HK1217900A1 (en) 2009-08-24 2015-07-20 Methods and compositions for preventing or treating opthalmic conditions
HK18107246.7A HK1247821A1 (zh) 2009-08-24 2018-06-01 用於预防或治疗眼科病症的方法和组合物

Country Status (17)

Country Link
US (8) US8470784B2 (fr)
EP (18) EP2470191B1 (fr)
JP (8) JP6120399B2 (fr)
CN (3) CN102625709A (fr)
CA (1) CA2772094C (fr)
DK (2) DK2470191T3 (fr)
ES (3) ES3036317T3 (fr)
FI (1) FI3708178T3 (fr)
HK (4) HK1204958A1 (fr)
HR (1) HRP20231277T1 (fr)
HU (1) HUE064800T2 (fr)
LT (1) LT3708178T (fr)
PL (2) PL3708178T3 (fr)
PT (2) PT3708178T (fr)
SI (2) SI3708178T1 (fr)
SM (1) SMT202300433T1 (fr)
WO (1) WO2011025734A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8403983B2 (en) 2008-09-29 2013-03-26 Cardiaq Valve Technologies, Inc. Heart valve
EP2845569A1 (fr) 2008-10-01 2015-03-11 Cardiaq Valve Technologies, Inc. Système d'administration pour implant vasculaire
CA2961053C (fr) 2009-04-15 2019-04-30 Edwards Lifesciences Cardiaq Llc Implant vasculaire et systeme d'introduction
SMT202300433T1 (it) * 2009-08-24 2024-01-10 Stealth Biotherapeutics Inc Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare
WO2011116007A1 (fr) * 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Thérapies de combinaison utilisant de la cyclosporine et des peptides cationiques aromatiques
WO2011137363A1 (fr) * 2010-04-30 2011-11-03 Allergan, Inc. Nouveau traitement pour la dégénérescence maculaire liée à l'âge et la maladie ischémique oculaire associée à l'activation du complément par le ciblage de la 5-lipoxygénase
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
EP2622443B1 (fr) 2010-10-01 2022-06-01 Z124 Geste de déplacement pour faire glisser dans une interface utilisateur
WO2012129427A2 (fr) * 2011-03-24 2012-09-27 Cornell University Peptides aromatiques cationiques et leurs utilisations
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
US8878794B2 (en) 2011-09-27 2014-11-04 Z124 State of screen info: easel
CN107312066A (zh) * 2011-12-09 2017-11-03 康德生物医疗技术公司 芳香族阳离子肽及其用途
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2013149172A1 (fr) * 2012-03-30 2013-10-03 Stealth Peptides International, Inc. Procédés et compositions pour la prévention et le traitement de la neuropathie
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法
EP2913062B1 (fr) * 2012-10-24 2019-05-08 Japan Innovative Therapeutics, Inc. Agent thérapeutique ou prophylactique pour la rétinopathie de prématurité et procédé de test pour la rétinopathie de prématurité
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
CN110339339A (zh) * 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
CN115990242A (zh) 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
US10583002B2 (en) 2013-03-11 2020-03-10 Neovasc Tiara Inc. Prosthetic valve with anti-pivoting mechanism
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
CA2916977A1 (fr) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methodes et compositions destinees a detecter et a diagnostiquer des maladies et des affections
US20160193278A1 (en) * 2013-08-01 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015023680A1 (fr) * 2013-08-12 2015-02-19 Stealth Peptides International, Inc. Polythérapie pour le traitement d'une lésion d'ischémie-reperfusion
WO2015061658A1 (fr) * 2013-10-25 2015-04-30 Children's Medical Center Corporation Procédés pour traiter ou prévenir des maladies vasculaires de la rétine
US9943563B2 (en) * 2013-12-02 2018-04-17 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
WO2015103577A1 (fr) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Méthodes et compositions pour prévenir ou traiter une atrophie optique dominante
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
AU2015243261B2 (en) 2014-04-10 2020-06-25 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
WO2015183988A1 (fr) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Compositions thérapeutiques comprenant de petites molécules thérapeutiques et leurs utilisations
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
ES2903397T3 (es) 2015-12-30 2022-04-01 Marshall Univ Research Corporation Composiciones y métodos para tratar la retinopatía
CN115160402A (zh) 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
AU2017249218B2 (en) 2016-04-11 2020-08-27 Arcuate Therapeutics, Inc. Chiral peptides
WO2017177262A1 (fr) 2016-04-11 2017-10-19 University Of Canberra Compositions ophtalmiques comprenant de la lévodopa, un antioxydant et un support aqueux
WO2018187400A1 (fr) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Formes cristallines de sel de boc-d-arg-dmt-lys-(boc)-phe-nh2
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
KR102349776B1 (ko) * 2017-11-17 2022-01-10 셀릭스 바이오 프라이빗 리미티드 눈 질환의 치료를 위한 조성물 및 방법
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
US11400070B2 (en) * 2018-05-03 2022-08-02 Alimera Sciences, Inc. Methods of treating retinal diseases
US20210330735A1 (en) * 2018-07-16 2021-10-28 Stealth Biotherapeutics Corp Compositions and methods for the treatment of traumatic optic neuropathy
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
AU2020206010A1 (en) * 2019-01-12 2021-07-22 Cellix Bio Private Limited Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
JP2020174859A (ja) * 2019-04-17 2020-10-29 学校法人日本医科大学 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法
WO2020214990A1 (fr) * 2019-04-17 2020-10-22 Ascidian Therapeutics, Inc. Lignée cellulaire abca4 et méthodes d'utilisation
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
KR20220012940A (ko) * 2019-05-28 2022-02-04 엘간 파마 리미티드 망막병증 치료용 조성물 및 방법
AU2021241476A1 (en) * 2020-03-25 2022-11-03 Aufbau Medical Innovations Limited Processes and agents for glaucoma
KR20230124625A (ko) * 2020-12-24 2023-08-25 산텐 세이야꾸 가부시키가이샤 에피나스틴 또는 그의 염과 황계 항산화제를 함유하는경피 투여용 의약 조성물
WO2023069255A1 (fr) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Procédés et compositions comprenant des peptidomimétiques pour le traitement, la prévention, l'inhibition, l'amélioration ou le retardement de l'apparition d'affections ophtalmiques
EP4419123A1 (fr) * 2021-10-20 2024-08-28 Stealth BioTherapeutics Inc. Procédés et compositions comprenant des peptidomimétiques pour le traitement, la prévention, l'inhibition, l'amélioration ou le retardement de l'apparition d'affections ophtalmiques
WO2023086873A1 (fr) * 2021-11-10 2023-05-19 Reverspah Llc Procédés et compositions de traitement du cancer
CN114099678A (zh) * 2021-11-23 2022-03-01 浙江大学 基于Keap1-Nrf2信号通路的晶状体损伤抑制剂
KR102662922B1 (ko) * 2022-05-31 2024-05-03 주식회사 세네릭스 신규의 d-아미노산 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2085865T3 (es) * 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JP2002505077A (ja) * 1997-12-10 2002-02-19 ワシントン大学 抗病原体システムおよびその使用方法
EP1071414A1 (fr) * 1998-04-24 2001-01-31 Mitokor Composes et methodes de traitement de maladies liees aux mitochondries
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6503713B1 (en) * 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
JP2001270832A (ja) * 2000-03-27 2001-10-02 Ito En Ltd 網膜障害予防剤
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
CA2493748A1 (fr) * 2002-08-14 2004-02-26 Medical College Of Georgia Research Institute, Inc. Methodes et compositions de traitement de troubles maculaires et retinaux
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20060172972A1 (en) 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
US7704954B2 (en) * 2003-05-01 2010-04-27 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
WO2005032481A2 (fr) * 2003-09-30 2005-04-14 Scios Inc. Dérivés de quinazoline en tant que médicaments
CA3024434A1 (fr) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methodes de reduction de lesions par oxydation
CA2562356A1 (fr) 2004-04-08 2005-10-27 Retmed Pty Ltd Traitement de pathologies ophtalmiques
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
JP4760111B2 (ja) 2005-04-26 2011-08-31 株式会社セガ 映像オブジェクト表現用データ構造生成プログラム、映像オブジェクト表現用データ構造生成方法、映像ソフト開発装置、映像処理プログラム、映像処理方法、映像処理装置、映像オブジェクト表現用データ構造、および、記録媒体
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
JP2007043629A (ja) * 2005-06-30 2007-02-15 Sony Corp グラフィック・ユーザ・インタフェース装置と操作入力処理方法及び双方向コミュニケーション装置
CA2615360A1 (fr) 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation et procedes d'administration d'agents actifs au plan ophtalmologique
CA2947343C (fr) * 2005-09-16 2019-04-30 Cornell Research Foundation, Inc. Methodes permettant de reduire l'expression de cd36
EP1932534A1 (fr) 2005-10-05 2008-06-18 Aqumen Biopharmaceuticals K.K. Procédé d'inhibition de l'angiogenèse à l'aide d'éphrine b2
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
TW200744627A (en) 2006-02-21 2007-12-16 Pfizer Prod Inc Methods for the treatment of macular degeneration and related eye conditions
EP2021026A1 (fr) * 2006-04-14 2009-02-11 Novartis AG Utilisation d'anticorps anti-il-1 pour le traitement de troubles ophtalmiques
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
DE102006042329B4 (de) * 2006-09-01 2008-08-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zum selektiven plasmachemischen Trockenätzen von auf Oberflächen von Silicium-Wafern ausgebildetem Phosphorsilikatglas
CA2672297A1 (fr) 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions et methodes de traitement de l'angiogenese pathologique et de la permeabilite vasculaire
JP2008195655A (ja) * 2007-02-14 2008-08-28 Kitasato Institute 糖尿病白内障の治療剤
JP2008247898A (ja) * 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
RU2460526C2 (ru) 2007-05-25 2012-09-10 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна
PT2252312E (pt) * 2008-02-07 2014-07-17 Univ Cornell Métodos de prevenção ou tratamento de resistência a insulina
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
EP3563862B1 (fr) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 pour la prévention des complications secondaires des brûlures
FR2945540B1 (fr) 2009-05-15 2012-06-08 Rhodia Operations Procede de preparation de mousse polyamide et mousse susceptible d'etre obtenue par ce procede
CN105031605A (zh) 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
SMT202300433T1 (it) * 2009-08-24 2024-01-10 Stealth Biotherapeutics Inc Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare
EP2848628A1 (fr) * 2010-01-25 2015-03-18 Cornell University Peptides aromatiques-cationiques et utilisations de ceux-ci
CA2790823A1 (fr) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Antioxydants a cible mitochondriale pour lutter contre un dysfonctionnement membranaire et l'atrophie des muscles squelettiques induits par une ventilation mecanique
JP2013532124A (ja) 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
CN105126071A (zh) 2011-06-14 2015-12-09 康肽德生物医药技术有限公司 芳香族阳离子肽及其用途
CA2916492A1 (fr) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Agents therapeutiques peptidiques, et leurs procedes d'utilisation
US20160199437A1 (en) * 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof

Also Published As

Publication number Publication date
EP2990049A1 (fr) 2016-03-02
SI3708178T1 (sl) 2024-01-31
US10188692B2 (en) 2019-01-29
EP3524256A1 (fr) 2019-08-14
JP2017141306A (ja) 2017-08-17
HUE064800T2 (hu) 2024-04-28
JP2020128431A (ja) 2020-08-27
JP2022001609A (ja) 2022-01-06
US20110177047A1 (en) 2011-07-21
CA2772094A1 (fr) 2011-03-03
JP2013502460A (ja) 2013-01-24
EP2813235A1 (fr) 2014-12-17
JP7642965B2 (ja) 2025-03-11
PT2470191E (pt) 2014-06-12
EP2962695A1 (fr) 2016-01-06
EP4302829B1 (fr) 2025-05-21
EP3485896A1 (fr) 2019-05-22
WO2011025734A1 (fr) 2011-03-03
EP4596049A3 (fr) 2025-08-13
PT3708178T (pt) 2023-11-16
EP4302829A2 (fr) 2024-01-10
JP2023179733A (ja) 2023-12-19
JP2018162329A (ja) 2018-10-18
US20160058825A1 (en) 2016-03-03
JP6120399B2 (ja) 2017-04-26
US20230381264A1 (en) 2023-11-30
DK2470191T3 (da) 2014-07-07
JP6332757B2 (ja) 2018-05-30
EP3708178A1 (fr) 2020-09-16
HK1206258A1 (en) 2016-01-08
SMT202300433T1 (it) 2024-01-10
DK3708178T3 (da) 2023-11-13
US9023807B2 (en) 2015-05-05
HK1217900A1 (en) 2017-01-27
EP3150215A1 (fr) 2017-04-05
EP4302829A3 (fr) 2024-03-27
EP2470191A1 (fr) 2012-07-04
CN102625709A (zh) 2012-08-01
EP2470191A4 (fr) 2013-04-17
US20210154259A1 (en) 2021-05-27
SI2470191T1 (sl) 2014-08-29
US8470784B2 (en) 2013-06-25
EP2826487A1 (fr) 2015-01-21
HRP20231277T1 (hr) 2024-02-02
JP2025181975A (ja) 2025-12-11
JP2016026188A (ja) 2016-02-12
EP3292868A1 (fr) 2018-03-14
US20170326197A1 (en) 2017-11-16
US9549963B2 (en) 2017-01-24
EP3338788A1 (fr) 2018-06-27
HK1247821A1 (zh) 2018-10-05
FI3708178T3 (fi) 2023-11-09
EP2957291A1 (fr) 2015-12-23
US20200061147A1 (en) 2020-02-27
HK1172833A1 (en) 2013-05-03
EP2470191B1 (fr) 2014-05-07
LT3708178T (lt) 2023-12-27
US11612633B2 (en) 2023-03-28
US11944662B2 (en) 2024-04-02
EP3175862A1 (fr) 2017-06-07
ES3036317T3 (en) 2025-09-17
ES2487633T3 (es) 2014-08-22
EP3124036A1 (fr) 2017-02-01
CN105056206A (zh) 2015-11-18
PL2470191T3 (pl) 2014-09-30
PL3708178T3 (pl) 2024-05-13
CA2772094C (fr) 2018-04-03
CN107412722A (zh) 2017-12-01
JP6381737B2 (ja) 2018-08-29
EP3318264A1 (fr) 2018-05-09
US20230346874A1 (en) 2023-11-02
EP3494983A1 (fr) 2019-06-12
EP4596049A2 (fr) 2025-08-06
US20140044689A1 (en) 2014-02-13
EP3708178B1 (fr) 2023-10-04
ES2964555T3 (es) 2024-04-08

Similar Documents

Publication Publication Date Title
US11944662B2 (en) Methods and compositions for preventing or treating ophthalmic conditions
HK40103778A (en) Peptide for use in preventing or treating macular degeneration
HK40037744A (en) Peptide for use in preventing or treating macular degeneration
HK40007730A (en) Methods and copositions for preventing or treating opthalmic conditions
HK40037744B (en) Peptide for use in preventing or treating macular degeneration
HK1219674A1 (en) Methods and compositions for preventing or treating opthalmic conditions
HK1172833B (en) Methods and compositions for preventing or treating ophthalmic conditions